Literature DB >> 22071119

Piperazine compounds as drugs of abuse.

M D Arbo1, M L Bastos, H F Carmo.   

Abstract

Synthetic drugs are among the most commonly abused drugs in the world. This abuse is widespread among young people, especially in the dance club and rave scenes. Over the last several years, piperazine derived drugs have appeared, mainly available via the internet, and sold as ecstasy pills or under the names of "Frenzy", "Bliss", "Charge", "Herbal ecstasy", "A2", "Legal X" and "Legal E". Although in the market piperazine designer drugs have the reputation of being safe, several experimental and epidemiological studies indicate risks for humans. Piperazine designer drugs can be divided into two classes, the benzylpiperazines such as N-benzylpiperazine (BZP) and its methylenedioxy analogue 1-(3,4-methylenedioxybenzyl)piperazine (MDBP), and the phenylpiperazines such as 1-(3-chlorophenyl)piperazine (mCPP), 1-(3-trifluoromethylphenyl)piperazine (TFMPP), and 1-(4-methoxyphenyl)piperazine (MeOPP). Toxicokinetic properties, including metabolic pathways, actions and effects in animals and humans, with some hypothesis of mechanism of action, and analytical approaches for the identification of these drugs are summarized in this review.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22071119     DOI: 10.1016/j.drugalcdep.2011.10.007

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  11 in total

1.  Investigations of Piperazine Derivatives as Intestinal Permeation Enhancers in Isolated Rat Intestinal Tissue Mucosae.

Authors:  V Stuettgen; D J Brayden
Journal:  AAPS J       Date:  2020-01-27       Impact factor: 4.009

2.  Twelve 4-(4-meth-oxy-phen-yl)piperazin-1-ium salts containing organic anions: supra-molecular assembly in one, two and three dimensions.

Authors:  Haruvegowda Kiran Kumar; Hemmige S Yathirajan; Sabine Foro; Christopher Glidewell
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2019-09-20

Review 3.  Nephrotoxic effects of designer drugs: synthetic is not better!

Authors:  Randy L Luciano; Mark A Perazella
Journal:  Nat Rev Nephrol       Date:  2014-03-25       Impact factor: 28.314

4.  Accidental Flibanserin Ingestion in Children Causing Acute Respiratory and Central Nervous System Depression: What Health Care Professionals Need to Know.

Authors:  Marcea B Whitaker; Miriam M Chehab; Christina Y Chang; Lynda V McCulley; Catherine A Sewell
Journal:  Obstet Gynecol       Date:  2022-03-10       Impact factor: 7.623

5.  An In Vitro Study of the Neurotoxic Effects of N-Benzylpiperazine: A Designer Drug of Abuse.

Authors:  Karolina Persona; Anna Polus; Joanna Góralska; Anna Gruca; Aldona Dembińska-Kieć; Wojciech Piekoszewski
Journal:  Neurotox Res       Date:  2016-02-09       Impact factor: 3.911

6.  Comparison of LC-MS and LC-DAD Methods of Detecting Abused Piperazine Designer Drugs.

Authors:  Anna Welz; Marcin Koba; Piotr Kośliński; Joanna Siódmiak
Journal:  J Clin Med       Date:  2022-03-22       Impact factor: 4.241

7.  Identification and characterization of new designer drug 4-fluoro-PV9 and α-PHP in the seized materials.

Authors:  Milena Majchrzak; Marcin Rojkiewicz; Rafał Celiński; Piotr Kuś; Mieczysław Sajewicz
Journal:  Forensic Toxicol       Date:  2015-10-13       Impact factor: 4.096

8.  Importance of Toxicokinetics to Assess the Utility of Zebrafish Larvae as Model for Psychoactive Drug Screening Using Meta-Chlorophenylpiperazine (mCPP) as Example.

Authors:  Krishna Tulasi Kirla; Ksenia J Groh; Michael Poetzsch; Rakesh Kumar Banote; Julita Stadnicka-Michalak; Rik I L Eggen; Kristin Schirmer; Thomas Kraemer
Journal:  Front Pharmacol       Date:  2018-04-26       Impact factor: 5.810

Review 9.  Designer drugs: mechanism of action and adverse effects.

Authors:  Dino Luethi; Matthias E Liechti
Journal:  Arch Toxicol       Date:  2020-04-06       Impact factor: 5.153

10.  Rapid Targeted Method of Detecting Abused Piperazine Designer Drugs.

Authors:  Anna Welz; Marcin Koba; Piotr Kośliński; Joanna Siódmiak
Journal:  J Clin Med       Date:  2021-12-12       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.